Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab (Q43622985)

25 November 2017

title

Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab (English)

1 reference

25 November 2017

0 references

1 reference

7

Kiyohiko Hatake

1 reference

25 November 2017

Satoshi Matsusaka

1

1 reference

25 November 2017

Yuji Mishima

2

1 reference

25 November 2017

Mitsukuni Suenaga

3

1 reference

25 November 2017

Yasuhito Terui

4

1 reference

25 November 2017

Ryoko Kuniyoshi

5

1 reference

25 November 2017

Nobuyuki Mizunuma

6

1 reference

25 November 2017

language of work or name

English

0 references

publication date

24 February 2011

1 reference

25 November 2017

1 reference

25 November 2017

volume

117

1 reference

25 November 2017

issue

17

1 reference

25 November 2017

page(s)

4026-4032

1 reference

Isolation of putative progenitor endothelial cells for angiogenesis

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Vascular endothelial growth factor receptor-2 induces survival of hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Origins of circulating endothelial cells and endothelial outgrowth from blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Blockade of the Stromal Cell–Derived Factor-1/CXCR4 Axis AttenuatesIn vivoTumor Growth by Inhibiting Angiogenesis in a Vascular Endothelial Growth Factor–Independent Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

inferred from DOI database lookup

7 January 2021

based on heuristic

Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25977

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.25977

1 reference

release_dmu7i2rbyzcs3c6ccvevv5to3m

25 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dmu7i2rbyzcs3c6ccvevv5to3m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference